Connection

Co-Authors

This is a "connection" page, showing publications co-authored by RONALD S WALTERS and DANIEL J BOOSER.
Connection Strength

0.316
  1. Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsed metastatic breast cancer: a phase II study. Am J Clin Oncol. 2000 Feb; 23(1):40-1.
    View in: PubMed
    Score: 0.045
  2. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-?. Invest New Drugs. 2018 12; 36(6):1103-1109.
    View in: PubMed
    Score: 0.041
  3. Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous-infusion 5-fluorouracil in metastatic breast cancer. J Immunother Emphasis Tumor Immunol. 1995 Oct; 18(3):185-7.
    View in: PubMed
    Score: 0.033
  4. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012 Mar 20; 30(9):930-5.
    View in: PubMed
    Score: 0.026
  5. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34.
    View in: PubMed
    Score: 0.025
  6. Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer. Clin Breast Cancer. 2008 Dec; 8(6):516-21.
    View in: PubMed
    Score: 0.021
  7. Phase II trial of 10-EDAM in the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2007 Jun; 60(1):61-7.
    View in: PubMed
    Score: 0.018
  8. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer. 2003 Jun 01; 97(11):2716-23.
    View in: PubMed
    Score: 0.014
  9. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002 May; 8(5):1073-9.
    View in: PubMed
    Score: 0.013
  10. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest. 2001; 19(5):459-66.
    View in: PubMed
    Score: 0.012
  11. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer. 2000 Dec 01; 89(11):2195-201.
    View in: PubMed
    Score: 0.012
  12. Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol. 2000 Apr; 23(2):117-21.
    View in: PubMed
    Score: 0.011
  13. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol. 1999 May; 17(5):1425-34.
    View in: PubMed
    Score: 0.011
  14. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol. 1999 Apr; 10(4):403-11.
    View in: PubMed
    Score: 0.011
  15. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1996 Oct; 14(10):2713-21.
    View in: PubMed
    Score: 0.009
  16. Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1994; 33(4):313-6.
    View in: PubMed
    Score: 0.007
  17. The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. J Natl Cancer Inst Monogr. 1993; (15):161-9.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.